Bier H
Department of Otorhinolaryngology, University of Düsseldorf, Germany.
Acta Otolaryngol. 1991;111(4):797-806. doi: 10.3109/00016489109138414.
In a previous report we have characterized cisplatin (CDDP)-resistant sublines (HLac 79-DDP1 to DDP4) of the recloned squamous cell head and neck cancer (SCHNC) line HLac 79-ML revealing significant alterations of glutathione (GSH) metabolism and drug accumulation. In order to overcome CDDP-resistance in HLac 79 cells we now investigated the effect of buthionine sulfoximine (BSO), a specific inhibitor of GSH synthesis, verapamil (VRP), a calcium channel blocker that has been found to modulate resistance towards a broad spectrum of antineoplastic drugs, cyclosporin A (CSA), an immunosuppressive agent probably affecting drug pharmacokinetics, and aphidicolin (APC), a fungal metabolite interfering with DNA repair through inhibition of DNA polymerase alpha, on HLac 79 CDDP-sensitivity. Using the colorimetric MTT assay, GSH depletion with BSO led to a significant decrease of the 50% inhibitory drug concentration (IC50) in all HLac 79 sublines by dose modifying factors (IC50 CDDP/IC50 BSO + CDDP) ranging from 1.8 to 3.3. VRP, CSA or APC were not effective to overcome CDDP resistance in HLac 79 cells. The potential of BSO to modulate CDDP resistance in vitro was tested in vivo in HLac 79 tumor bearing NMRI nu-nu mice subsequently. Oral administration of BSO 7 days prior and during (days -7 to 8) CDDP treatment (3 mg/kg bw i.p. days 0, 4, 8) produced a significant prolongation of mean survival time mean as compared to chemotherapy alone. This held true for both the maternal line ML in terms of chemosensitization (CDDP: mean = 40.2 +/- 15.9 days vs. CDDP + BSO: mean = 80.3 +/- 30.4 days, p less than 0.001) and the CDDP resistant subline DDP4 in terms of partially overcoming secondary drug resistance (CDDP: mean = 56.5 +/- 13.6 days vs. CDDP + BSO: mean = 72.5 +/- 15.8 days, p less than 0.001). Enhanced toxicity of combined BSO and CDDP treatment manifested by transient 10% reduction of animal mean body weight.
在之前的一份报告中,我们对重新克隆的头颈部鳞状细胞癌(SCHNC)系HLac 79-ML的顺铂(CDDP)耐药亚系(HLac 79-DDP1至DDP4)进行了表征,发现其谷胱甘肽(GSH)代谢和药物蓄积有显著改变。为了克服HLac 79细胞中的CDDP耐药性,我们现在研究了丁硫氨酸亚砜胺(BSO,一种GSH合成的特异性抑制剂)、维拉帕米(VRP,一种已被发现可调节对多种抗肿瘤药物耐药性的钙通道阻滞剂)、环孢素A(CSA,一种可能影响药物药代动力学的免疫抑制剂)和阿非科林(APC,一种通过抑制DNA聚合酶α干扰DNA修复的真菌代谢产物)对HLac 79细胞CDDP敏感性的影响。使用比色MTT法,BSO导致GSH耗竭,所有HLac 79亚系的50%抑制药物浓度(IC50)均显著降低,剂量修正因子(IC50 CDDP/IC50 BSO + CDDP)范围为1.8至3.3。VRP、CSA或APC在克服HLac 79细胞中的CDDP耐药性方面无效。随后在荷HLac 79肿瘤的NMRI裸鼠体内测试了BSO在体外调节CDDP耐药性的潜力。在CDDP治疗(第0、4、8天腹腔注射3 mg/kg体重)前7天及治疗期间(第-7至8天)口服BSO,与单独化疗相比,平均生存时间显著延长。这在母系ML的化疗增敏方面(CDDP:平均 = 40.2 +/- 15.9天 vs. CDDP + BSO:平均 = 80.3 +/- 30.4天,p < 0.001)以及CDDP耐药亚系DDP4的部分克服继发性耐药方面(CDDP:平均 = 56.5 +/- 13.6天 vs. CDDP + BSO:平均 = 72.5 +/- 15.8天,p < 0.001)均成立。联合BSO和CDDP治疗的增强毒性表现为动物平均体重短暂降低10%。